Haya Therapeutics

1. Executive Summary (Confidence: High)

Haya Therapeutics is a pioneering precision medicine company focused on "Programming Lasting Health" through the exploration of the regulatory genome, also known as "genome dark matter". Headquartered in Lausanne, Switzerland, with laboratories in San Diego, Haya utilizes a multimodal functional genomics platform to decode the 98% of the human genome that does not code for proteins. Having successfully raised $65 million in Series A funding, the company is advancing its lead candidate, HTX-001, into clinical trials for heart failure, specifically targeting cardiac fibrosis. By drugging long non-coding RNAs (lncRNAs) that causally drive disease, Haya aims to reprogram "sick" cell states back to healthy ones, offering a new paradigm for treating common, chronic, and age-associated conditions.